4D Molecular Therapeutics (FDMT) Net Cash Flow (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Net Cash Flow for 7 consecutive years, with $12.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 177.46% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at -$61.0 million (up 57.04% YoY), while the FY2025 annual figure was -$89.1 million, up 10.7% from the prior year.
• Net Cash Flow grew to $12.2 million in Q1 2026 per FDMT's latest filing, from $11.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $157.7 million in Q2 2023 and bottomed at -$86.5 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$4.7 million across 5 years, with a median of -$5.2 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 859.1% — and 2025, when it slumped 1779.37%.
• 4D Molecular Therapeutics' Net Cash Flow stood at -$55.9 million in 2022, then surged by 52.51% to -$26.6 million in 2023, then sank by 43.78% to -$38.2 million in 2024, then soared by 130.59% to $11.7 million in 2025, then increased by 4.8% to $12.2 million in 2026.
• Business Quant data shows FDMT's Net Cash Flow at $12.2 million in Q1 2026, $11.7 million in Q4 2025, and -$28.6 million in Q3 2025.